Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers developed an AI-powered platform called VitaDetect, which screens for vitamin deficiencies using image analysis of nails, tongue, and skin, aiming to provide an accessible and early-stage detection tool in resource-limited settings.

This article reviews the current FDA-approved treatments for severe pediatric alopecia areata, including the use of Janus kinase inhibitors, but reports no new clinical findings.

This study re-examined the structure of lanceolate endings in rat vibrissae, suggesting that their apical cones may function as a transducer site for detecting hair movements.

This study observed a high prevalence of severe markers among pediatric alopecia areata patients, identifying AA subtotalis as more frequent, with nail changes and various hair markers suggesting progression to severe forms.

This study describes a successful reconstructive A-T flap surgery on a 74-year-old male with a 35mm basal cell carcinoma on the scalp, resulting in a 50mm defect, with no complications and optimal functional and cosmetic outcomes reported.

Raltegravir may cause hair loss in some patients.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This study found that serum survivin levels were significantly lower in alopecia areata patients, correlating with disease severity and progression, suggesting it could play a role in the condition's pathogenesis.

This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.

This study found significant associations between certain MICA variants and haplotypes with alopecia areata, suggesting MICA as a potential candidate gene linked to the disease's susceptibility and severity.

This review discusses the development and potential therapeutic applications of adenosine receptor agonists and positive allosteric modulators, noting that while many clinical trials have been unsuccessful, initial results for new compounds are promising.

This study found that young male patients with grade III and IV androgenetic alopecia had elevated levels of serum amyloid A3, suggesting a higher risk of developing atherosclerosis compared to those without the condition.

This report describes a case of alopecia areata incognita in a 6-year-old child, marked by sudden diffuse hair loss without bald patches, typically observed in adults.

This study reports that a single injection of stromal vascular fraction (SVF) cells into the scalp of patients with androgenetic alopecia significantly increased hair density and thickness within 3 to 6 months, with no observed side effects.

This study demonstrated that the Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata cases with high sensitivity and specificity in a dermatology clinic setting.

This study found that non-bleeding adverse events associated with NOACs affect multiple organ systems, emphasizing the importance of clinical vigilance. Specific NOACs like dabigatran, apixaban, edoxaban, and rivaroxaban were linked to distinct adverse reactions, including metabolic imbalances, thyroid disorders, and menstrual irregularities.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

This study observed that biodegradable PVA/agar films with incorporated Achillea millefolium L. essential oil, especially at 1% (v/v), demonstrated good mechanical performance and selective antibacterial activity against E. coli, suggesting their potential as wound dressings.

In this study, autologous cellular micrografts significantly improved hair parameters in androgenic alopecia patients, showing promise as an effective treatment without dangerous side effects.

This study found that A-FABP serum levels were significantly higher in male patients with androgenetic alopecia compared to controls, and the authors concluded that A-FABP could serve as a biomarker for early detection of this condition.

This study at Shandong Provincial Hospital evaluated interventional embolization for scalp arteriovenous fistulas, finding a cure rate of 85.71% among 21 patients, with swelling as a common postoperative complication, suggesting this method is both effective and safe.

This study found a statistically significant association between androgenetic alopecia and coronary artery disease in men, with higher grades of alopecia, especially involving the vertex, indicating a greater risk.

In this retrospective study at Toyama University Hospital, amoxapine was reported to significantly improve semen volume, sperm concentration, and total sperm count in 17 men with ejaculatory disorders, with no observed side effects over an average of 13 months of therapy.

In this study, ALR was found to enhance both the proliferation and osteogenic differentiation of mouse bone marrow mesenchymal stem cells, potentially through specific signaling pathways.

This study found that orally administering the CCR5 inhibitor Maraviroc improved hair loss in 4 out of 5 mice with alopecia areata and also reduced the development of the condition, evidenced by decreased CCR5+ T-cell infiltration in treated mice.

Perinevoid alopecia can be effectively treated with non-invasive corticosteroids.

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

This abstract contains only supplementary material information and reports no new research findings.

This study found that in noise-exposed FVB/NJ mice and cell models, ivacaftor reduced oxidative stress and hearing damage by maintaining CFTR function and increasing Nrf2 expression, suggesting its potential for treating noise-induced hearing loss.